Clinical spectrum of reversible posterior leukoencephalopathy syndrome

Archives of Neurology

Volumn 65, Issue 2, 2008, Pages 205-210

  Lee, Vivien H ^a   Wijdicks, Eelco F M ^b   Manno, Edward M ^b   Rabinstein, Alejandro A ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN DAMAGE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIALYSIS; DISEASE DURATION; ELECTROENCEPHALOGRAM; FEMALE; GRAY MATTER; HEADACHE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEUKOENCEPHALOPATHY; LUMBAR PUNCTURE; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SEIZURE; SYSTOLIC BLOOD PRESSURE; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; BLOOD PRESSURE; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEADACHE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; RECURRENCE; RETROSPECTIVE STUDIES; SEIZURES; TOMOGRAPHY, X-RAY COMPUTED; VISION DISORDERS;

EID: 39049139815     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2007.46     Document Type: Article

References (28)

1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500.
2. Schwaighofer BW, Hesselink JR, Healy ME. MR demonstration of reversible brain abnormalities in eclampsia. J Comput Assist Tomogr. 1989;13(2):310-312.
3. Hauser RA, Lacey DM, Knight MR. Hypertensive encephalopathy: magnetic resonance imaging demonstration of reversible cortical and white matter lesions. Arch Neurol. 1988;45(10):1078-1083.
4. Appignani BA, Bhadelia RA, Blacklow SC, Wang AK, Roland SF, Freeman RB. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. AJR Am J Roentgenol. 1996;166(3):683-688.
5. Small SL, Fukui MB, Bramblett GT, Eidelman BH. Immunosuppression-induced leukoencephalopathy from tacrolimus (FK506). Ann Neurol. 1996;40(4):575-580.
6. Truwit CL, Denaro CP, Lake JR, DeMarco T. MR imaging of reversible cyclosporin A-induced neurotoxicity. AJNR Am J Neuroradiol. 1991;12(4):651-659.
7. Singh N, Bonham A, Fukui M. Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. Transplantation. 2000;69(4):467-472.
8. Chester EM, Agamanolis DP, Banker BQ, Victor M. Hypertensive encephalopathy: a clinicopathologic study of 20 cases. Neurology. 1978;28(9 Pt 1):928-939.
9. Schwartz RB. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(26):1743.
10. Antunes NL, Small TN, George D, Boulad F, Lis E. Posterior leukoencephalopathy syndrome may not be reversible. Pediatr Neurol. 1999;20(3):241-243.
11. Schwartz RB, Jones KM, Kalina P, et al. Hypertensive encephalopathy. AJR Am J Roentgenol. 1992;159(2):379-383.
12. Wartenberg KE, Patsalides AD, Yepes M. Transient diffusion-weighted imaging changes in a patient with reversible leukoencephalopathy syndrome. Acta Radiol. 2004;45(6):674-678.
13. Ahn KJ, You WJ, Jeong SL, et al. Atypical manifestations of reversible posterior leukoencephalopathy syndrome. Neuroradiology. 2004;46(12):978-983.
14. Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2000;21(7):1199-1206.
15. Jarosz JM, Howlett DC, Cox TC, Bingham JB. Cyclosporine-related reversible posterior leukoencephalopathy: MRI. Neuroradiology. 1997;39(10):711-715.
16. Ay H, Buonanno FS, Schaefer PW, et al. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998;51(5):1369-1376.
17. Schwartz RB, Mulkern RV, Gudbjartsson H, Jolesz F. Diffusion-weighted MR imaging in hypertensive encephalopathy: clues to pathogenesis. AJNR Am J Neuroradiol. 1998;19(5):859-862.
18. Shimono T, Miki Y, Toyoda H, et al. MRI imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients. Eur Radiol. 2003;13(5):986-993.
19. Schaefer PW, Buonanno FS, Gonzalez RG, Schwamm LH. Diffusion-weighted imaging discriminates between cytotoxic and vasogenic edema in a patient with eclampsia. Stroke. 1997;28(5):1082-1085.
20. Koch S, Rabinstein A, Falcone S, Forteza A. Diffusion-weighted imaging shows cytotoxic and vasogenic edema in eclampsia. AJNR Am J Neuroradiol. 2001;22(6):1068-1070.
21. Provenzale JM, Petrella JR, Cruz LC Jr, Wong JC, Engelter S, Barboriak DP. Quantitative assessment of diffusion abnormalities in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2001;22(8):1455-1461.
22. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol. 2002;23(6):1038-1048.
23. Ugurel MS, Hayakawa M. Implications of post-gadolinium MRI results in 13 cases with posterior reversible encephalopathy syndrome. Eur J Radiol. 2005;53(3):441-449.
24. Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cylosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol. 2001;22(10):1901-1914.
25. Oliverio PJ, Restrepo L, Mitchell SA, Tornatore CS, Frankel SR. Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. AJNR Am J Neuroradiol. 2000;21(7):1251-1254.
26. Kitaguchi H, Tomimoto H, Miki Y, et al. A brainstem variant of reversible posterior leukoencephalopathy syndrome. Neuroradiology. 2005;47(9):652-656.
27. Hagemann G, Ugur T, Witte OW, Fitzek C. Recurrent posterior reversible encephalopathy syndrome (PRES). J Hum Hypertens. 2004;18(4):287-289.
28. Schwartz RB, Bravo SM, Klufas RA, et al. Cyclosporine neurotoxicity and its relationship to hypertensive encephalopathy: CT and MR findings in 16 cases. AJR Am J Roentgenol. 1995;165(3):627-631.